Illustrative med spa valuation with concentrated provider revenue

This fictional teaching case evaluates a $3.1 million med spa where one provider generates sixty percent of revenue. It models $475,000 normalized EBITDA, a production-loss downside, and an assumed $2.48 million offer with contingent consideration. The calculation separates seller cash, earnout exposure, and a hypothetical reserve without predicting retention.

What is concentrated in the fictional practice?

A med spa earns $3.1 million annual revenue, of which one provider produces $1.86 million. That is sixty percent of total revenue. The provider plans to remain, but the buyer needs to understand the relationship between individual production, shared staff, patient return behavior, and business systems.

Concentration is a starting measurement. It does not establish that the provider is disloyal, that patients will leave, or that revenue will fall by a fixed amount after a sale. The buyer should investigate the actual operating dependencies rather than attach an automatic discount to a percentage.

What is the supported starting earnings figure?

Assume reported EBITDA is $515,000. Add $21,000 documented nonrecurring legal cost, subtract $43,000 incremental coordination expense, and subtract an $18,000 membership revenue-recognition correction. Normalized EBITDA is $475,000.

The adjustment schedule should connect to payroll, agreements, ledgers, and service-period records. The $18,000 correction is a teaching assumption about historical earnings, not an instruction to subtract every outstanding membership obligation from EBITDA. Actual accounting needs evidence about what was earned, deferred, and fulfilled.

Which provider evidence is useful?

Analyze production by month, service, location, hours, discounts, refunds, and patient cohort. Compare patients seen by other qualified providers and distinguish appointments booked under a name from services actually delivered. Verify whether the data includes deposits or only earned service revenue.

Review employment or contractor documents, compensation, benefits, schedules, professional responsibilities, and reasons for staying. Contracts and incentives can support continuity, but they do not guarantee production or patient decisions. Qualified counsel should evaluate enforceability, clinical authority, and any proposed restrictions.

The California Medical Board’s practice guidance illustrates professional-control and departure considerations in that state. The HIPAA definitions in 45 CFR 160.103 establish a starting point for identifying regulated roles, not blanket permission to circulate patient lists in diligence. Use approved aggregate analysis and controlled review methods.

How does the retained-production price sensitivity work?

Apply invented factors of 5.0 and 5.8 to $475,000 normalized EBITDA. The resulting teaching range is $2.375 million to $2.755 million. These are not observed transaction multiples and do not establish fair value for a provider-concentrated practice.

Assume the parties discuss $2.48 million consideration in a retained-provider scenario. That case presumes continuity under the proposed arrangements; it is not a forecast. The buyer should document the support for continued staffing, capacity, referrals, patient return patterns, and access to needed services.

Do not compare the assumed retained-case price with downside earnings as though the figures represent the same facts. The purpose of a scenario model is to expose a change in operating conditions. Price negotiations should identify which case the offer relies on and how the parties share unresolved transition exposure.

What happens if lead-provider production falls?

Assume twenty percent of the lead provider’s $1.86 million production is lost: $372,000 annual revenue. Assume fifty-five percent contribution on that lost production after variable costs that actually disappear. The modeled earnings reduction is $204,600, leaving $270,400 EBITDA.

The fifty-five percent contribution assumption must not be confused with total business EBITDA margin. It estimates revenue less avoidable variable costs in this particular downside. Fixed rent, core staff, administrative support, and other costs may continue. A real case requires service-level cost evidence and practical timing.

Using invented downside factors of 3.9 and 4.6 gives $1,054,560 to $1,243,840. The lower factors are separate teaching assumptions about risk, not a rule that provider losses mechanically change the market multiple. Show both denominator and factor changes so the reader can see which assumption drives the outcome.

How could an earnout change the offer?

Assume the $2.48 million proposal includes $1.984 million closing cash and a maximum $496,000 earnout. This is an eighty percent cash and twenty percent contingent split of consideration. The earnout maximum is not guaranteed and must not be counted as money received at closing.

Define the measurement period, relevant production, pricing, provider assignment, discounts, expenses, data access, dispute process, and buyer conduct obligations. If the buyer controls schedules and marketing while the earnout depends on revenue, the agreement should address those interactions explicitly.

A provider-specific target can also create operational tension if it encourages unnecessary concentration or conflicts with appropriate professional decisions. Counsel and clinical leadership must evaluate the actual incentives. Neither a financial model nor an earnout contract should override patient needs, professional judgment, or lawful role boundaries.

What are the seller’s immediate proceeds?

From $1.984 million closing cash, subtract $284,000 existing debt, $117,000 transaction fees, and $83,000 escrow. Immediate cash before taxes is $1.5 million. An arbitrary hypothetical $312,000 tax-planning reserve leaves $1.188 million unreserved immediate cash.

The IRS guidance on selling a business explains that allocation and asset character affect actual tax treatment. This reserve does not calculate liability, imply a recommended percentage, or determine the treatment of a future earnout. A CPA must evaluate the actual proposal and contingent-payment terms.

The seller should compare a lower all-cash proposal with the earnout offer on separate dimensions: immediate cash, collection risk, conditions, continuing duties, and possible upside. Adding the full earnout and escrow to current available cash would obscure both timing and uncertainty.

What should the transition plan measure?

1. Preserve a documented baseline of production and patient-return metrics.
2. Confirm qualified staffing, schedules, and administrative support.
3. Identify services that lack practical backup coverage.
4. Approve patient communication and records access through the appropriate process.
5. Track cash, contribution, attendance, and staff stability alongside revenue.
6. Separate actual operating changes from reporting-system differences.

A plan should assign responsibility to the buyer, seller, provider, and managers without assuming the concentrated provider must solve every integration issue. Consider what happens if leave, illness, reduced hours, or an ordinary employment change occurs even when no one breaches an agreement.

Continuity should improve the operating business rather than exist only as a purchase agreement condition. Shared systems, appropriate cross-coverage, clear compensation, and realistic capacity can reduce dependence over time, but any change needs to respect professional roles and patient choices.

Which assumptions should be refreshed before closing?

Update the provider schedule, compensation, retention discussions, and recent production after diligence. Compare them with the baseline used in the offer and identify material changes before funding. A model prepared months earlier may no longer describe current capacity. Record whether an updated fact changes earnings, transition spending, contingent terms, or the decision to proceed.

How should this example inform a real decision?

Use the valuation hub, buyer roadmap, seller guidance, and operations hub. The med spa diligence guide supports evidence collection, the Four-Number Med Spa Valuation Screen separates earnings measures, and the offer-to-proceeds bridge separates cash from contingency.

The useful result is not a universal provider discount. It is an explicit comparison of documented earnings, a stated downside, assumed pricing, and the offer’s risk allocation. Replace the fictional inputs with verified information before evaluating whether the actual deal is attractive or affordable.

Educational analysis prepared with AI-assisted research for The Med Spa Broker. “Last reviewed” records the source and editorial check date; it does not imply review by an attorney, clinician, or independent appraiser. Read our editorial standards.